Insight

Joe Lennerz: Quickly sharing a fantastic paper on tumour infiltrating lymphocytes in triple-negative breast cancer

Photo of Joe Lennerz from pathologyoutlines.com

Apr 12, 2024, 05:34

Joe Lennerz: Quickly sharing a fantastic paper on tumour infiltrating lymphocytes in triple-negative breast cancer

Joe Lennerz, Chief Scientific Officer at BostonGene, shared on LinkedIn:

“Quickly sharing a fantastic paper on tumour infiltrating lymphocytes (TIL) in triple-negative breast cancer (TNBC). Bottom line: In patients with early-stage TNBC who did not undergo adjuvant or neoadjuvant chemotherapy, breast cancer tissue with a higher abundance of TIL levels was associated with significantly better survival.

These results suggest that breast tissue TIL abundance is a prognostic factor for patients with early-stage TNBC. Link to publication.”

Source: Joe Lennerz/LinkedIn

adjuvant chemotherapy BostonGene Breast Cancer cancer Joe Lennerz neoadjuvant chemotherapy OncoDaily Oncology TNBC triple-negative breast cancer tumour infiltrating lymphocytes (TIL)

Richard Gere and Alejandra Gere to Join Second Global OncoThon on February 15 for Fight Against Childhood Cancer

Mesothelioma Guideline Updates from ASCO 2024: Key Advances in Diagnosis and Treatment

Oncologist Near Me - Lynn Schuchter: A Pioneering Leader in Cancer Care and Melanoma Research

NIH lowered the maximum indirect cost rate research institutions can charge the government to 15%

Stanley Tucci and Throat Cancer: How He Went Against, How He Survived, and More